NCT01671332 is a Phase 2 clinical trial of Docetaxel in Carcinoma, Non Small Cell Lung, sponsored by University of Wisconsin, Madison.

Who is sponsoring NCT01671332?

NCT01671332 is sponsored by University of Wisconsin, Madison.

What drugs are being tested in NCT01671332?

Interventions in NCT01671332: Docetaxel, Suramin, Docetaxel.

What condition does NCT01671332 study?

NCT01671332 studies Carcinoma, Non Small Cell Lung.

Is NCT01671332 still recruiting?

NCT01671332 is currently completed. Last updated 7 May 2020.

Are results published for NCT01671332?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-05-07 · How we verify

NCT01671332

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Phase II Study of Suramin and Docetaxel Versus Docetaxel in Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Completed Phase 2 Results posted Last updated 7 May 2020

What this trial tests

Phase 2 trial testing Docetaxel in Carcinoma, Non Small Cell Lung in 80 participants. Completed in 16 June 2016.

Timeline

1 June 2012

Primary endpoint
11 June 2015

16 June 2016

Quick facts

Lead sponsor	University of Wisconsin, Madison
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 June 2012
Primary completion	11 June 2015
Estimated completion	16 June 2016
Sites	2 locations across United States

Drugs / interventions tested

Docetaxel (Docetaxel) — full drug profile →
Suramin — full drug profile →
Docetaxel (Docetaxel) — full drug profile →

Conditions studied

Carcinoma, Non Small Cell Lung — all drugs for Carcinoma, Non Small Cell Lung →

Sponsor

University of Wisconsin, Madison

Who can join

18 and older, any sex, with Carcinoma, Non Small Cell Lung. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Progression-free Survival in Months
Time frame: Up to 1 year
Compare progression-free survival (PFS) in participants with advanced NSCLC treated with docetaxel with or without suramin after failure of first-line chemotherapy. PFS is defined as the duration of time from the time of randomization to time of disease progression or death, whichever occurs first.

Sponsor's own description

The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.
Cheng Y, He C, Wang M, Ma X, et al · · 2019 · cited 760× · PMID 31871779 · DOI 10.1038/s41392-019-0095-0
100 Years of Suramin.
Wiedemar N, Hauser DA, Mäser P. · · 2020 · cited 135× · PMID 31844000 · DOI 10.1128/aac.01168-19
Autophagy Modulators in Coronavirus Diseases: A Double Strike in Viral Burden and Inflammation.
Silva RCMC, Ribeiro JS, da Silva GPD, da Costa LJ, et al · · 2022 · cited 16× · PMID 35433503 · DOI 10.3389/fcimb.2022.845368
Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment.
Zhu G, Wan X, Wu W, Jia L, et al · · 2025 · cited 3× · PMID 40657202 · DOI 10.1002/smsc.202400479
Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic-cell clearance to therapeutic targeting.
Yang Q, Yan J, Yang Q. · · 2026 · cited 1× · PMID 41601343 · DOI 10.1002/ctm2.70601

Verify or expand the search:

Other trials of Docetaxel

Trials testing the same drug.

NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
NCT07361484 — Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy a · Phase 3 · not yet recruiting
NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07487896 — A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esopha · Phase 3 · not yet recruiting

Other recruiting trials for Carcinoma, Non Small Cell Lung

Currently open trials in the same condition.

NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
NCT06974734 — A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies · Phase 1 · active not recruiting

Other University of Wisconsin, Madison trials

Trials by the same sponsor.

NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts · Phase 1 · recruiting
NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin · NA · enrolling by invitation
NCT07470723 — The ORIGIN-FH Study · NA · recruiting
NCT06975657 — Well-being Skills for Reentry · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01671332 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
Last refreshed: 7 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01671332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing